THERAPEUTIC USES OF NICOTINE
The uses of nicotine, analogues, precursors or derivatives thereof for treatment of inflammatory, infectious, candidal or degenerative diseases of the joint, central nervous system, kidney, lung, and liver, depression, obesity, bone disease and the like are described. The various diseases, disorders or conditions can be improved by means of intensification of the actions of α-MSH, whose release is affected by the use of nicotine, analogues, precursors or derivatives thereof, which can increase and/or reduce the bioavailability of α-MSH in blood and/or central or peripheral tissues to accentuate or diminish the effect of the α-MSH for therapeutic and/or prophylactic purposes..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Europäisches Patentamt - (2018) vom: 28. Sept. Zur Gesamtaufnahme - year:2018 |
---|
Sprache: |
Unbestimmt |
---|
Beteiligte Personen: |
HERRERA ARTURO SOLIS [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-28, Last updated: 2021-03-11 |
---|
Patentnummer: |
US2012270907 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA007285469 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA007285469 | ||
003 | DE-627 | ||
005 | 20230504071015.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210531s2018 xx |||||o 00| ||und c | ||
035 | |a (DE-627)EPA007285469 | ||
035 | |a (EPA)US2012270907 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a und | ||
100 | 0 | |a HERRERA ARTURO SOLIS |e verfasserin |4 aut | |
245 | 1 | 0 | |a THERAPEUTIC USES OF NICOTINE |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-28, Last updated: 2021-03-11 | ||
520 | |a The uses of nicotine, analogues, precursors or derivatives thereof for treatment of inflammatory, infectious, candidal or degenerative diseases of the joint, central nervous system, kidney, lung, and liver, depression, obesity, bone disease and the like are described. The various diseases, disorders or conditions can be improved by means of intensification of the actions of α-MSH, whose release is affected by the use of nicotine, analogues, precursors or derivatives thereof, which can increase and/or reduce the bioavailability of α-MSH in blood and/or central or peripheral tissues to accentuate or diminish the effect of the α-MSH for therapeutic and/or prophylactic purposes. | ||
650 | 4 | |a A61K | |
650 | 4 | |a che | |
650 | 4 | |a A61P | |
650 | 4 | |a 615 | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2018) vom: 28. Sept. |
773 | 1 | 8 | |g year:2018 |g day:28 |g month:09 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/searchResults?DB=EPODOC&locale=en_EP&query=US2012270907A1 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
912 | |a SSG-OLC-PHA | ||
936 | u | w | |j 2018 |b 28 |c 09 |
951 | |a AR | ||
952 | |j 2018 |b 28 |c 09 |